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ABSTRACT
Purpose Following a TV documentary in 2013, there was a tremendous increase in low dose naltrexone (LDN) use in a wide range of
unapproved indications in Norway. We aim to describe the extent of this sudden and unprecedented increase in LDN prescribing, to char-
acterize patients and LDN prescribers, and to estimate LDN dose sizes.
Methods LDN prescriptions recorded in the Norwegian Prescription Database (NorPD) in 2013 and 2014, and sales data not recorded in
NorPD from the only Norwegian LDN manufacturer were included in the study.
Results According to NorPD, 15 297 patients (0.3% of population) collected at least one LDN prescription. The actual number of users
was higher as at least 23% of total sales were not recorded in NorPD. After an initial wave, there was a steady stream of new and persistent
users throughout the study period. Median patient age was 52 years, and 74% of patients were female. Median daily dose was 3.7mg.
Twenty percent of all doctors and 71% of general medicine practitioners registered in Norway in 2014 prescribed LDN at least once.
Conclusions The TV documentary on LDN in Norway was followed by a large increase in LDN prescribing, and the proportion of LDN
users went from an insignificant number to 0.3% of the population. There was a high willingness to use and prescribe off label despite limited
evidence. Observed median LDN dose, and age and gender distribution were as expected in typical LDN using patients. © 2016 The Au-
thors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.
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INTRODUCTION
Naltrexone is an opioid antagonist originally used to
treat opioid and alcohol addiction.1,2 Over the past
two decades, low dose naltrexone (LDN—typically
<5mg/day) has gained popularity as an off-label
treatment of several autoimmune diseases.3 Some
studies including a limited number of patients and with
short duration of follow-up are inconclusive on effi-
cacy in multiple sclerosis (MS), Crohn’s disease,
chronic pain, and fibromyalgia.4–7 In February 2016,
LDN was rated as the most effective among 35 MS
treatments at CureTogether, an online social network
for patients.8 No studies have described patients receiv-
ing long time off-label LDN therapy, discontinuation
rates, or proportion of persistent users. There are no
guidelines on LDN dosing, but some authors suggest
daily doses of 3–4.5mg.9 To our knowledge, the actual
doses taken by LDN using patients have not been char-
acterized in pharmacoepidemiological studies. LDN is
relatively unknown among doctors and should be con-
sidered as alternative or complementary therapy be-
cause high quality clinical and epidemiological
studies are lacking.
Several possible mechanisms of action have been
suggested, mostly in which endogenous opioids play
a role.9 Naltrexone has been used for decades, and
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the safety profile when used for approved indications
is well known.
Naltrexone is a low-cost generic drug with limited
commercial potential. If proven efficacious for one or
more of the mentioned patient groups, it will be a
cheap supplement or competitor to several standard
treatments.
On 27 February 2013, the biggest commercial TV-
channel station in Norway (TV2) aired a documentary
on the alleged effects of LDN. Patients with severe MS
explained how the use of LDN had almost normalized
their function.10 Following the documentary, there
was a large increase in the awareness and consumption
of LDN in Norway among patients with a wide range
of diagnoses. In social media, Norwegian LDN groups
gained thousands of new members within few weeks.
A preliminary search in the Norwegian Prescription
Database (NorPD) revealed that the number of naltre-
xone users increased from 14 in 2012 to more than
11000 in 2013.11 The sudden increase in the number
of users sheds light on mass media impact on patient
and prescriber behavior when it comes to alternative
or complementary medical treatments.
The main objectives of this study were to determine
the extent of this sudden and unprecedented tsunami
like increase in LDN prescribing by characterizing
the LDN prescription patterns, and to calculate the
mean daily dose among persistent users. The
secondary objective was to describe the prescriber
demographics and specialties.
METHODS
Study design and data sources
This drug utilization cohort study used data from the
NorPD on dispensed prescriptions of LDN covering
the entire Norwegian population. In addition, we
obtained sales statistics for 2013 and 2014 from the
only Norwegian manufacturer of naltrexone 3-mg
tablets to account for unrecorded prescribing of LDN.
NorPD contains individual data on all prescriptions
dispensed since 2004 to the entire Norwegian popula-
tion living outside institutions (hospitals and nursing
homes). Details on NorPD are published elsewhere.12
In short, NorPD contains a unique pseudonym for
the personal identifier and demographic data on patient
and prescriber, the specialty of the prescriber, the
Anatomical Therapeutic Chemical (ATC)-code and
the amount of drug prescribed, date of dispensing,
and location of the dispensing pharmacy. It is possible
to follow prescriptions to individual patients, and both
reimbursed and non-reimbursed prescriptions are
recorded. Only prescriptions on products that have a
product identifying number are recorded, and pre-
parations compounded by pharmacies according to a
physician’s prescription are not included. The database
contains no information on the indication for therapy,
but has disease codes (ICD-10 or ICPC-2) for reim-
bursed medications. The database is operated by the
Norwegian Institute of Public Health.13 We used the
following variables in this study: person identifier for
patient and prescriber, patient and prescriber age and
sex, prescriber specialty, ATC-code, product number,
date of dispensing, and dispensed volume in defined
daily doses (DDD). Prescriptions are recorded in
NorPD only when they are actually dispensed. For a
fee, NorPD provided a data file according to their data
access procedures.
All patients included in NorPD with a prescription
on LDN (ATC-code N07B B04) in 2013 or 2014 were
included in the cohort, and all recorded LDN prescrip-
tions from 1 January 2013 through 31 December 2014
were included. Only one LDN product (Naltrekson
Kragerø 3-mg tab, Kragerø tablettproduksjon AS)
was recorded. This product was assigned a product
identifying number (361181) on 15 May 2013.
Incident use was identified by the first patient specific
appearance of this product number in NorPD.
Outcomes
The main outcome was the number of LDN prescrip-
tions in NorPD. In order to estimate LDN daily doses
and time between dispenses, we followed patients that
repeatedly collected LDN prescriptions. Average daily
dose was calculated based on number of days between
repeated dispenses and amount dispensed. We defined
patients retrieving five or more naltrexone prescrip-
tions as persistent users.
We calculated median age and gender distribution
for all prescriptions. For patients collecting more than
one prescription, we calculated time since last
dispense. We identified the total number of prescribers
and corresponding specialties, both in absolute
numbers and as proportions of all doctors.
Study size was determined by the number of
dispensed LDN prescriptions in 2013 and 2014.
The specialist doctor classification is in accordance
with the official EU harmonized Norwegian specialty
structure.14
Statistical methods
Data were processed in Microsoft Excel 2010, SPSS
23, and StataMP 14. No statistical tests were used,
because the total population was covered. Percentiles
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(10 and 90 and median) for age and average daily dose
were calculated.
Ethics
The project protocol was submitted to the Regional
Committee for Medical and Health Research Ethics
of Northern Norway. The committee concluded that
disclosure was not mandatory, because the data were
pseudonymized. The local privacy ombudsman for
research at the University Hospital of Northern
Norway approved the project. For Norwegian central
health registries like NorPD, consent from individual
patients is by law not required.
RESULTS
In 2013 through 2014, 15297 patients (0.3% of total
population in Norway) collected 48006 boxes of
100 tablets of LDN from 45216 prescriptions at
Norwegian pharmacies according to NorPD. In addi-
tion, the manufacturer sold 14506 boxes (23.2% of
total sales) directly to pharmacies and wholesalers
before the product identification number was assigned
on 15 May 2013.15 This amount was not captured by
NorPD. Prior to 2013, Kragerø tablettproduksjon had
an average monthly sale of approximately 100 boxes
of LDN to wholesalers or local pharmacies, also not
captured by the NorPD.15
In the NorPD database, there were 18500 dispenses
to 11247 unique patients in 2013, of which 6320
(56%) also retrieved at least one LDN prescription in
2014. In 2014, there were 26716 dispenses to 10370
unique patients. Total NorPD observation time (from
first LDN collected to 31 December 2014) was
247478 patient months, of which 140158 patient
months for individuals that collected LDN more than
once.
Figure 1 shows the number of LDN dispenses in
NorPD by month. After the TV documentary, the
number of monthly dispenses reached a maximum of
2855 in September 2013. The number of dispensed
LDN prescriptions then stabilized between 2000 and
2500 per month. First time dispenses (incident use)
reached a maximum of 2083 in June 2013, but
stabilized around 2–300 per month throughout 2014.
In addition, the number of patients with five or more
naltrexone dispenses or more has increased steadily
since December 2013.
Mean and median patient age was 52years, range 4
to 102years, and 74% of patients were female. Eighty
children under 16years were dispensed 161 LDN
prescriptions. Altogether, 9256 patients (60.5% of
total) collected two or more LDN prescriptions in
the study period. For repeated LDN prescriptions,
median time between two dispenses were 83days,
mean 92days. There was a decreasing proportion of
females, increasing age, and decreasing time since
last dispense with increasing number of dispenses
(Table 1).
Median estimated daily dose based on dispensed
amount and time between dispenses was 3.7mg, mean
5.3mg. Increasing dispense number was associated


























Figure 1. Dispensed low dose naltrexone (LDN) prescriptions recorded in Norwegian Prescription Database (NorPD) by month. Total and repeated prescrip-
tions. A documentary on LDN was aired 27 February 2013, and a LDN product was first included in NorPD from 15 May 2013 [Color figure can be viewed at
wileyonlinelibrary.com]
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LDN dispenses were from 4695 different pre-
scribers. This accounts for 19.7% of all working
doctors registered in Norway in 2014.16 Fifteen per
cent of the prescribers accounted for 50% of the
dispensed prescriptions. Median number of LDN
prescriptions per prescriber was 5 and 90% prescribed
22 LDN prescriptions or less. There were 939 (19.1%)
one-time prescribers. Fourteen doctors had more than
100 LDN prescriptions. One doctor prescribed LDN
569 times, accounting for more than 1% of all LDN
prescriptions in Norway in 2013 and 2014. See
Table 2 for prescriber characteristics. Specialists
Table 1. Frequencies of first (incident) and repeated and low dose naltrexone (LDN) prescriptions, with age and gender distribution. Time since last dispense
for repeated LDN prescriptions
Collected LDN
prescription # N % females Patient age Time since last LDN dispense (days)
Mean Median 10 percentile 90 percentile Mean Median 10 percentile 90 percentile
1 15 297 73.8 50.4 51 32 68 — — — —
2 9256 73.9 51.3 51 34 68 103.8 92 53 167
3 6770 74.0 52.1 52 35 69 99.2 89 52 161
4 5074 74.6 52.6 53 36 69 93.7 86 49 147
5 3616 74.6 52.9 53 37 69 85.5 79 44 130
6 2291 74.6 53.3 53 37 69 78.6 73 44 120
7 1348 73.4 53.3 53 38 69 69.3 68 35 104
8 719 72.5 53.9 53 39 70 61.9 63 24 93
9 308 70.1 55.2 54 40 71 52.2 54 15 79
10 or more 537 65.9 62.0 55 42 71 23.5 43 13 73
All 45 216 73.9 51.7 52 34 69 92.4 83* 44* 147*






























Figure 2. Median and mean naltrexone doses for all patients collecting more than LDN prescription [Color figure can be viewed at wileyonlinelibrary.com]
Table 2. Age and gender of Norwegian LDN prescribers by specialist status.
All prescribers Certified specialists Prescribers without specialty
N % Mean age N % Mean age N % Mean age
All prescribers 4695 100 46.0 2668 100 52 2027 100 38.1
Male 2823 60.1 48.4 1771 66.4 53.5 1052 51.9 39.9
Female 1868 39.8 42.5 893 33.5 49.3 975 48.1 36.2
Age and gender unknown 4 0.1 NA 4 0.1 NA 0 0 —
low dose naltrexone use in norway 139
© 2016 The Authors. Pharmacoepidemiology and Drug Safety
Published by John Wiley & Sons Ltd.
Pharmacoepidemiology and Drug Safety, 2017; 26: 136–142
DOI: 10.1002/pds
constituted 57% of all prescribers, and 82.6% of LDN
prescribing specialists were general practitioners.
The mean age of the LDN prescriber was 46years,
1.5years older than the average working doctor in
Norway. Female doctors accounted for 39.8% of
LDN prescribers, but 33.5% of LDN prescriptions,
both lower than the proportion of working female
doctors in Norway (44.5%). Male prescribers were
older than the female, both among specialists and
non-specialists. Specialties representing the most
frequent prescribers are presented in Table 3. More
than 71% of general medicine specialists wrote at least
one prescription. Among specialists in public health,
gastroenterology, rheumatology, and among specia-
lists in physical medicine and rehabilitation, more than
one in 10 were LDN prescribers.
DISCUSSION
Key results
In this study, we have quantified the extent and iden-
tified prescription patterns of the unprecedented
increase in LDN prescribing following a Norwegian
TV documentary in 2013. According to NorPD,
15297 patients collected a total number of 45216
LDN prescriptions in 2013 and 2014, compared to
almost zero in the preceding years. In addition, the
manufacturer sold 14506 boxes of LDN that were not
captured by NorPD. The maximum monthly number
of NorPD recorded LDN prescriptions reached 2855
after the TV documentary, and the number of LDN pre-
scriptions to new users in NorPD stabilized at 2–300
per month. Sixty per cent of the patients collected
two or more LDN prescriptions, and during the 2-year
study period, the number of patients that collected five
or more prescriptions increased. Of LDN prescriptions
in NorPD, 74% were dispensed to females, and median
age of patients at the time of the first dispense was
52years. Median time between repeated dispenses
was 83days. We estimated a median daily naltrexone
dose of 3.7mg for patients that retrieved more than
one prescription. One in five doctors registered in
Norway prescribed LDN in 2013 or 2014.
Interpretation
The TV documentary was followed by an extreme
increase of dispensed LDN prescriptions, and our
study indicates that LDN has become more than an
ephemeral phenomenon in Norway. LDN was regu-
larly used as off-label treatment by many patients,
and there was a steady recruitment of new users
throughout 2014. According to the manufacturer, the
LDN annual sale is relatively stable. In 2015, 22511
boxes were sold to wholesalers.15 The number of
LDN users in Norway increased from a handful indi-
viduals to approximately 3000 per million in 2013
and 2014. One milligram of naltrexone (low dose
formulation) was priced to approximately NOK 1.33
(USD 0.15), which means that the Norwegian LDN
market in 2014 was equivalent to approximately
USD 260000 per million capita. Autoimmune
diseases are more common in women, and the high
proportion of female LDN users is therefore as
expected. In addition, there is some evidence suggest-
ing that LDN might be efficacious against fibromyal-
gia and similar conditions.6,7 LDN probably gained
attention and popularity in these female-dominated
patient groups in Norway after the TV documentary.
The observed median age is as expected for these
patient groups. The overall estimated median naltre-
xone dose of 3.7mg is representative for typical
LDN doses, which according to the largest Norwegian
LDN user forum (www.ldn.no), range from 0.75mg to
6mg per day.17 Mean doses are higher than median
doses, reflecting a small number of high dose naltre-
xone users. We observed increased LDN doses with
increasing number of dispenses. One possible explana-
tion is that some patients tried increasing doses to get
the desired effect.
Most doctors only wrote one or two prescriptions,
leaving most of the LDN prescribing to a limited num-
ber of doctors. Considering the massive attention LDN
has received among MS patients, the proportion of
prescribing neurologists is lower than we expected.
We have not identified other pharmacoepide-
miological studies on LDN, and the few clinical stud-
ies are mostly uncontrolled, or studies with few
Table 3. The 15 most frequent medical specialties among LDN pre-
scribers. Frequency and proportion of LDN prescribers within each spe-




General practice 2290 71.4
Public health 147 26.9






General surgery 29 2.3
Physical medicine and rehabilitation 23 10.8
Rheumatology 23 10.8
Gynecology and obstetrics 21 2.7
Occupational health 18 6.7
Orthopedic surgery 16 2.5
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participants. To our knowledge, this Norwegian
sudden surge in LDN use is unparalleled, and
Norway probably had the world’s highest LDN pre-
scription rate in 2013 and 2014.
The high proportion of persistent LDN users is of
considerable interest and warrants further studies. This
group should be characterized on indication for use,
possible comorbidities, and concurrent medication use.
A majority of Norwegian GPs prescribed LDN in the
study. This indicates a high willingness to prescribe
off-label with limited evidence of safety and efficacy.
This impression is reinforced by the fact that LDN
was prescribed to children as young as 4years.
Limitations
The completeness of NorPD is normally considered as
a major strength. Unfortunately, the LDN product was
not assigned a national product identity number until
15 May 2013, and the volume sold before this date
cannot easily be linked to patients or prescribers.
Consequently, the number of users and prescribers is
probably higher than the numbers reflected from the
NorPD, and we are unable to identify incident users
with certainty. We observed a maximum of LDN
dispenses in September 2013, but the use (including
unrecorded LDN) probably peaked earlier. In the first
weeks following the TV documentary, the situation
was extraordinary. Shortly after the documentary, the
Norwegian manufacturer of LDN tablets was unable
to meet the demand, and possibly some patients
diluted 50-mg naltrexone tablets for LDN use accor-
ding to instructions available on the Internet.18,19
However, prescriptions in NorPD for such use were
indistinguishable from naltrexone to approved indica-
tions and were not included in our material. Private
import from internet pharmacies or pharmacies abroad
may have occurred, but the extent of this is unknown.
From the second half of 2013 and for 2014, the pro-
ducer was able to supply the market, and LDN use
from sources not captured by NorPD was probably
negligible. In most cases, the dispensed amount of
LDN was one box of 100 tablets.
The number of persistent users is estimated from
NorPD data and is probably underestimated in our
study. We have defined persistent use as collection of
five or more LDN prescriptions. With the observed
median daily dose, five collected boxes of LDN would
be enough for approximately half the days in the study
period. However, there were patients in our material
who collected LDN with very long time intervals.
Some probably used as little as a quarter of a tablet
per day, which means that one box lasted for 400days.
These were not identified as persistent users despite
probable continuous use for more than a year.
Towards the end of the study period, there were also
incident users where observation time was too short
to identify persistence.
We emphasize that we have neither examined indi-
cations, nor the efficacy or safety of LDN use. Many
patients became persistent users of LDN, and this
may be interpreted as a perceived acceptable effect
and safety profile among these patients. This cannot
be considered as a proof of LDN treatment efficacy
for any condition. Still, the persistent use among thou-
sands of LDN users and the widespread willingness to
prescribe LDN are clear signals that robust clinical
studies on untraditional use of naltrexone are needed.
CONCLUSION
Our study demonstrates how a single TV documentary
combined with “viral” spread on social media most
likely had a massive impact on patient LDN demand
and prescriber behavior. Similar LDN “tsunamis”
may hit other shores at any time.
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KEY POINTS
• Low dose naltrexone (LDN) is used as off-label
treatment of several autoimmune and other
diseases.
• A TV documentary in 2013 probably led to a
huge increase in the awareness and consumption
of LDN in Norway.
• More than 15000 new LDN users in Norway
were recorded after the TV documentary, most
of them collected more than one prescription.
• Among persistent LDN users, median daily dose
was 3.7mg.
• LDN was prescribed at least once by 71% of
Norwegian general practitioners, indicating a
great willingness to prescribe off label with lim-
ited evidence of efficacy.
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